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INTRODUCTORY PARAGRAPH 
 
Latent autoimmune diabetes in adults (LADA) shares clinical features with both type 1 diabetes 
(T1D), including the presence of autoimmune autoantibodies, and type 2 diabetes (T2D), with 
adult age of onset, features of metabolic syndrome and initial insulin independence1,2. Despite 
being at least as prevalent as T1D4, the genetic basis of LADA remains largely 
uncharacterized1,4, except for limited candidate gene analyses suggesting a degree of shared 
genetic susceptibility with both T1D and T2D4–14. We therefore performed the first genome-wide 
association study of LADA. Together with HLA and gene set enrichment analyses, our data 
indicate that the leading signals are shared with T1D, but a T2D genetic component is also 
present. We report a novel signal at PFKFB3, encoding a known regulator of glycolysis in 
energy stressed cells, potentially bridging autoimmunity and metabolism. Furthermore, we 
observed mutually exclusive genetic co-heritability between LADA and immune traits 
(associated with T1D) as well as LADA and metabolic/anthropometric traits (associated with 
T2D), suggesting that the T2D genetic component operates as a modifier of the LADA 
phenotype. 
  
MAIN TEXT 
 
Although commonly referred to as ‘type 1.5 diabetes,’ the etiological relationship between 
LADA and both T1D and T2D is not fully elucidated. In many populations, LADA is at least as 
prevalent as T1D3, but is frequently misdiagnosed as T2D1,4,15,16 given its presentation without 
need for insulin. As such, LADA subjects could be present in cohort studies for T2D that do not 
screen out autoantibody-positive cases, potentially resulting in the identification of associations 
for T2D that are etiologically related to autoimmunity. This challenge is increasingly acute as 
increasingly larger data sets are assembled to identify additional, common genetic risk factors of 
smaller effect sizes. Indeed, reflecting this concern, recent genome-wide association study 
(GWAS) analyses of T2D have reported associations at T1D-associated regions such as HLA-
DQA1 in European ancestry populations17 and HLA-B and INS-IGF2 in African ancestry 
populations18. While the most recent T2D GWAS17 claims their signals do not likely represent 
patients with autoimmune diabetes, they queried only a single T1D SNP for the HLA, although 
we note that their lead SNP at HLA-DQA1 (rs9271775) in fact tags the established T1D-
associated haplotype HLA-DRB1*15- HLA-DQB1*0602 via proxy SNP rs3135388 (r2= 0.653). 
As such, understanding the genetic etiology of LADA will not only aid the much needed 
characterization of this relatively common form of diabetes, but will also facilitate our 
understanding of both T1D and T2D. 
To date, relatively limited candidate gene studies have been carried out for LADA, but have  
supported a role for both T1D and T2D risk loci2,4–13,19; however, no systematic genome-wide 
appraisal of LADA has been performed. To address this, we conducted the first GWAS of 
LADA cases (n = 2,713) versus population-based controls (n = 5,439) of European ancestry in a 
discovery meta-analysis setting (Supplementary Table 1). Four signals achieved genome-wide 
significance (P < 5x10-8), all at established T1D risk loci (HLA, PTPN22, INS, and SH2B3; 
Table 1), despite the adequate power of our study design to detect the strongest T2D-like effects 
(Supplementary Table 2). Pathway analysis with DEPICT20 for signals at P < 10-5 supported a 
strong immune role in the pathogenesis of LADA (Supplementary Tables 3-4), with GSEA 
implicating ‘abnormal cytotoxic T cell physiology’ (nominal P = 6.39 x 10-7) as well as the 
‘mTOR subnetwork’ (P = 6.03 x 10-5) and ‘cell cycle’ (P = 1.67 x 10-5) as also seen in a previous 
epigenome-wide association study of T1D,17 and immune system tissue types, including ‘natural 
killer cells’ and ‘T lymphocytes’ (nominal P = 0.0079 and 0.0082, respectively). This is 
consistent with previous reports of these cell types playing a role in the pathogenesis of T1D21–23 
and LADA24–26. 
Using LADA cases and population samples from an additional two study centers, we 
attempted replication of 13 signals with suggestive association (P < 5x10-5) (Supplementary 
Table 5). We observed a novel signal at 10p15.1 between the two established T1D loci at IL2RA 
and PRKCQ, which achieved borderline genome-wide significance (rs1983890-C, OR (95% CI) 
= 1.22 (1.14-1.32), P = 5.06 x 10-8) (Fig. 1A-B). As our LADA signal was in moderate to low 
LD with established T1D-associated alleles (Supplementary Table 6), we conditioned on the 
T1D SNPs and observed that rs1983890 remained strongly associated with LADA (OR (95% CI) 
= 1.15 (1.12-1.18), P = 1.7 x 10-7) (Fig. 1C). DEPICT gene prioritization analysis20 identified the 
gene encoding ‘6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3’ (PFKFB3), the nearest 
gene to the LADA signal, as the most likely candidate (Supplementary Table 7). Previous 
studies strongly support this gene as a plausible biological candidate, as PFKFB3 plays a key 
regulatory role in insulin-activated glycolysis in energy stressed cells27,28. Furthermore, previous 
studies have linked PFKFB3 to both autoimmune diseases (e.g., rheumatoid arthritis, Crohn’s 
disease, and celiac disease29–32), as well as T2D biology via insulin resistence33–37.  
Several additional variants with suggestive association to LADA overlapped previously 
documented T1D associations, including rs11755527 (BACH2) and rs941576 (DLK1). Taking a 
candidate approach, we extracted 68 established T1D-associated loci from the LADA vs. 
population controls meta-analysis, and found that 18 of these 68 loci yielded association with 
LADA after multiple-test correction (P < 3.6 x 10-4, Supplementary Table 8). Taking a similar 
candidate approach with 70 established T2D loci, none surpassed the significance threshold; 
however, at the nominal significance level (P < 0.05), 12 T1D and 14 T2D variants were 
associated with LADA, all having the same direction of effect as on T1D and T2D, respectively, 
except for the T2D locus CILP2 (rs10401969-T, OR = 0.80 (0.72-0.91), P = 4.9 x 10-4).  
In terms of T2D-associated loci, our results differ from previous candidate studies. For 
instance, our previously reported HNF1A7 locus was not observed in this setting.  Furthermore, 
while previous studies showed an association for the leading T2D risk locus at TCF7L2 with 
LADA,6,12 potentially providing a link between T2D and autoimmune diabetes,  our data does 
not support this finding (Supplementary Table 9)  (LADA vs. population controls, rs7903146-
T: OR (95% CI) = 1.006 (0.924-1.095), P = 0.896) despite the adequate power of our study 
design to detect the leading T2D-like signals (Supplementary Table 2). To understand the 
evidence supporting the previous association, we looked at the allele frequencies of the lead 
variant in each contributing cohort. This revealed that the difference in risk allele frequency 
between cases and controls was cohort-specific, and may be explained by cohort differences in 
LADA inclusion criteria (see Supplementary Table 1 and Supplementary Note) or by 
differences in allele frequencies between ActionLADA cases and our controls. Another 
possibility is that inclusion or exclusion of T2D patients from control cohorts would affect the 
frequency of the risk allele; however, sensitivity analysis with control sets that either excluded or 
included diabetic patients in Swedish and Danish samples showed the persistence of an 
association (Supplementary Table 10), although not at the genome-wide significance level. 
Next, we compared LADA with T2D at the genome-wide level. Similar to the results of 
LADA vs. population controls, LADA (n = 2,858) vs. T2D (n = 10,444) yielded genome-wide 
significance for the same four T1D risk loci, as well as for the T1D risk BACH2 locus 
(rs6908626)38 (Table 1). As such, comparing LADA cases with both the general population and 
with T2D cases has implied that LADA is genetically more similar to T1D, comparable to the 
findings of previous reports7,39. We went on to perform a GWAS of LADA (n = 2,533) vs. T1D 
(n = 971) to assess whether any differences could be detected. Our results showed that only the 
HLA region was significantly different, representing a relative depletion of the lead signal 
among LADA cases when compared to T1D cases (rs9273368-A, OR (95% CI) = 0.340 (0.289-
0.399), P = 8.69 x 10-40; Table 1). To further investigate differences in the HLA region between 
LADA and T1D cases, we imputed this region using SNP2HLA40 in 2,159 ActionLADA + 
CHOP + Swedish LADA cases and 1,990 T1D cases (WTCCC41) and compared the frequencies 
of the leading T1D-associated HLA haplotypes (Supplementary Table 11). After removing 
haplotypes with less than 1% frequency, fifteen known T1D-associated HLA haplotypes were 
tested for association in LADA compared to T1D. Eleven T1D haplotypes were significantly 
different in frequency between LADA and T1D cases after correction for multiple testing (P < 
0.003), with all but four being protective against T1D42. The four T1D susceptibility haplotypes, 
HLA-DRB1*0301-DQA1*0501-DQB1*0201, HLA-DRB1*0401-DQA1*0301-DQB1*0302, 
HLA-DRB1*0404-DQA1*0301-DQB1*0302, and HLA-DRB1*0405-DQA1*0301-
DQB1*030242, had significantly less impact in LADA. This could be partly explained by the 
established age gradient in HLA frequencies seen in T1D patients43; however, the HLA risk 
genotype frequency has been shown to differ also between LADA patients and T1D patients with 
age at onset >35 yrs13,44. Future studies of the differences in HLA risk haplotypes between T1D 
and LADA are therefore warranted. 
Taken collectively, GWAS and HLA haplotype analysis based on established associations, 
along with GSEA analyses, supports the hypothesis that the strongest genetic risk loci for LADA 
are shared with T1D, but that established T2D alleles also appear to play a role, albeit to a lesser 
degree. To further evaluate this hypothesis beyond established sites by leveraging data from the 
entire genome, we estimated genetic correlation among LADA, T1D, T2D, and related traits 
using LD score regression (LDSC) (leveraging the LDSC v.1.0.0 python package45 or the LD-
hub website46,47, http://ldsc.broadinstitute.org). First, we observed that T1D is, as expected, 
genetically correlated with autoimmune traits such as rheumatoid arthritis (rg (SE) = 0.452 
(0.162), P = 0.005) and systemic lupus erythematosus (rg (SE) = 0.364 (0.134), P = 0.007) (Fig. 
2; Supplementary Table 12). Additionally, T2D is strongly correlated with metabolic, 
glycemic, and anthropometric traits such as waist circumference (rg (SE) = 0.401 (0.04), P = 
3.73 x 10-23) and fasting insulin (rg (SE) = 0.483 (0.095), P = 3.90 x 10-7). However, strikingly, 
T1D and T2D were negatively genetically correlated (rg (SE) = -0.273 (0.092), P = 0.003), 
consistent with previous reports of opposite effects at established sites (e.g., CTRB1, at which the 
T1D risk allele (rs7202877-T) is protective for T2D and vice versa48), although a genome-wide 
negative correlation has not been previously described to our knowledge. It remains unclear 
whether this negative correlation is due to underlying biology or the mutual exclusion of T1D 
patients from T2D studies and vice-versa. Notably, LADA was positively genetically correlated 
with both T1D (rg (SE) = 0.379 (0.182), P = 0.037) and autoimmune traits, as well as T2D (rg 
(SE) = 0.309 (0.105), P = 0.003) and metabolic/anthropometric traits. Thus, our LADA sample 
shares genetic etiology with both a T1D-like autoimmune component and a T2D-like 
metabolic/anthropometric component that are mutually exclusive. GADA assays have a 
specificity of 95–98%, so by implication, some GADA-positive cases can be incorrectly 
classified as T2D cases; these should represent only a very small minority of cases and as such 
will not largely bias our results. Conversely, the small percentage of T2D cases misclassified as 
LADA patients could affect the estimate of genetic correlation between LADA and T2D to a 
small degree; however, this impact must be negligible given that we do not observe a positive 
correlation between T1D and T2D. Nevertheless, our findings lead to the hypothesis that the 
polygenic component that contributes susceptibility to T2D acts as a modifier to T1D risk, either 
as a ‘second hit’ in individuals who have moderate underlying autoimmune susceptibility that is 
insufficient to trigger childhood T1D but greater than that of the general population, or as a 
component that delays diabetes onset by protecting against autoimmune beta cell destruction 
earlier in life. 
In conclusion, in this first GWAS of LADA, we show that although the leading genome-wide 
significant signals point towards LADA as being a late-onset form of T1D, there is both a 
reduced potency of key T1D-associated HLA haplotypes and the presence of a T2D-like genetic 
component. Further in-depth studies are necessary to address how LADA develops, as well as a 
need for functional studies to investigate how the glycolytic regulator PFKFB3 is situated at the 
intersection of autoimmune and metabolic diabetes. Furthermore, our LADA dataset should act 
as a resource to help mitigate the unaccounted presence of autoimmune diabetic patients in T2D 
GWAS going forward. 
ONLINE METHODS 
 
Study subjects  
LADA cases were included from cohorts of European ancestry (Supplementary Table 1), 
including ‘ActionLada-Plus,’ All New Diabetics In Scania (ANDIS), the Botnia Study, 
Copenhagen LADA (including samples from Danish Centre for strategic Research in Type 2 
Diabetes (DD2), Vejle Biobank, Odense University Hospital (OUH), Copenhagen Insulin and 
Metformin Therapy trial (CIMT), Inter99, and Steno Diabetes Center (SDC)), Diabetes Registry 
Vasa (DIREVA), GoDARTS, Nord-Trøndelag Health Study (HUNT), and Scania Diabetes 
Registry (SDR). Controls were either population-based (including samples from the Bone 
Mineral Density in Childhood Study (BMDCS), Copenhagen controls (with samples from the 
1936 Birth Cohort and ADDITION-PRO), GoDARTS, HUNT, and the Malmö Diet and Cancer 
study) or contained T1D or T2D cases (including samples from GoDARTs, DIREVA, HUNT, 
and SDR). 
Inclusion and exclusion criteria for LADA, T1D, T2D, and population controls varied by cohort 
(see Supplementary Table 1 and Supplementary Note for details). In general, LADA was 
defined by an age at diagnosis older than 20, 30 or 35 years, with some cohorts restricting the 
upper age limit to 70 years; the presence of diabetes-associated autoimmune autoantibodies, in 
particular GADA-positivity; and the lack of insulin requirement for 6 months or 1 year after 
diagnosis. In some cases, C-peptide level was also used as a filter.  
 
Genotyping and imputation 
Each respective cohort performed genome-wide genotyping on the Illumina CoreExome chip, 
the Illumina OmniExpressExome chip, or the Affymetrix 6 chip. Cases and controls from each 
study center were matched on the same genotyping chip to reduce batch effects. Standard post-
genotyping quality control was performed, including sample exclusions for ambiguous gender, 
call rate < 95%, and any duplicate or related individuals (pi_hat ≥ 0.2), and SNP exclusions for 
monomorphic SNPs, SNPs with MAF < 0.05, and SNPs with missingness rate > 0.05. The 
Haplotype Reference Consortium (HRC) imputation service (URL) was utilized to perform 
imputation for autosomal SNPs.  
 
Genome-wide association and meta-analysis: LADACTRL, LADAT1D, and LADAT2D 
SNPtest 49 was used by each respective cohort to perform case-control GWAS of LADA (n = 
2,713) vs. population controls (n = 5,439),  LADA (n = 2,533) vs. T1D cases (n = 971), and 
LADA (n = 2,858) vs. T2D cases (n = 10,444), including sex and the first principal components 
as covariates (see Supplementary Table 1 for cohort-specific covariates).  
After GWAS, filtering was performed centrally to include only SNPs with a MAF > 0.05, INFO 
quality score > 0.4, and a Hardy-Weinberg equilibrium P > 1x10-7. Meta-analysis was then 
performed for LADA vs. population controls, LADA vs. T1D, and LADA vs. T2D with 
GWAMA50 with two rounds of genomic control (Supplementary Table 13). 
Signals in the secondary tier (P = 1 x 10-6 – 5 x 10-8) for the LADA vs. population controls 
analysis were followed up in the GODARTS and HUNT cohorts (LADA, n = 345; controls, n = 
1,664) and meta-analyzed with the discovery set (total LADA, n = 3,058; controls, n = 7,103) to 
assess whether any novel signals would reach genome-wide significance.  
 
Conditional analysis 
Approximate conditional analysis for known T1D-associated loci was carried out for the 
LADACTRL summary statistics results for the 10p15.1 locus using Genome-wide Complex 
Trait Analysis (GCTA)51,52. For this locus, LADACTRL + HUNT summary statistics were 
conditioned on the following T1D-associated SNPs: rs6183966053, rs1079579153, rs709053054, 
rs1225130755, rs4129512153, and rs1125874755. For 12q24.3, two of the T1D-associated SNPs 
(rs318450455 and rs65317853 were in high LD (r2 > 0.9) with our lead SNP, and the MHC, 
PTPN22, and INS loci were not conditioned as the top signals were identified as T1D-associated 
SNPs. 
 
LD Score Regression 
To test for genetic correlations genome-wide between LADA, T1D, T2D, and health-related 
outcomes, we used LD score (LDSC) regression either through the LDSC v.1.0.0 python 
package45 or the LD-hub website46,47 (http://ldsc.broadinstitute.org/#). Health-related outcomes 
that were genetically correlated with LADA at P < 0.05 were queried for their correlations to 
T1D54 and T2D48. Details on the GWAS that contributed summary statistics for these 
comparisons can be found on the LDSC website. 
 
Pathway analysis 
DEPICT pathway analysis20 was used to perform gene set enrichment, tissue enrichment, and 
gene prioritization analyses. 
 
HLA imputation/analysis 
The HLA imputation software SNP2HLA40 was used to impute chromosome 6 in ActionLADA-
Plus (n = 1,365), Swedish LADA cases (n = 794), BMDCS (n = 1,056) and WTCCC T1D cases 
(n = 1,990). HLA alleles with 4-digit resolution were imputed. The R package ‘BIGDAWG’ 
(https://cran.r-project.org/web/packages/BIGDAWG)56 was used to test for allele frequency 
differences for established T1D-associated HLA haplotypes between LADA versus T1D, as well 
as LADA versus BMDCS. Haplotypes with frequencies less than 1% across LADA, T1D, and 
BMDCS were removed from the analysis given that rare haplotypes can result in unstable 
variance estimates and unreliable test statistics.  
 
LD between T2D HLA-DQB1 lead SNP and T1D-associated haplotypes 
rs9271775 was used to check for evidence of linkage disequilibrium between the top signal near 
HLA-DQA1 reported to be associated with  T2D in a recent reported analysis17 and T1D-
associated HLA haplotypes (Table 2). Tag SNPs for HLA alleles were obtained from de Bakker 
et al.57. LADA (n = 1,210) and BMDCS (n = 1,056) chromosome 6 data (imputed as described 
above by SNP2HLA40) was leveraged to calculate pairwise LD between rs9271775 and tag SNPs 
using PLINK58. Information for eight tag SNPs of T1D-associated haplotypes (Table 2) were 
available for testing. 
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Figure 1. LocusZoom plots for the PFKFB3 locus. (A) In LADA vs. population controls with 
the addition of replication samples, rs1983890 reached borderline genome-wide significance. (B) 
This signal lies in between two T1D-associated loci at 10p15.1 (Bradfield 2011). (C) When we 
conditioned on the two known T1D loci, the signal in LADA remained. LocusZoom plots were 
constructed to show the association data of SNPs 400kb upstream and downstream of the lead 
LADA-associated signal at rs1983890.   
 
  
Figure 2. LD score regression (LDSC) analysis. We tested for genome-wide genetic 
correlations between LADA, T1D, T2D, and health-related outcomes. The MHC region was 
excluded prior to these analyses. Outcomes that were genetically correlated with LADA at P < 
0.05 were queried for their correlations to T1D54 and T2D48. Red represents a negative 
correlation, while blue represents a positive correlation. *, P = 0.01-0.05; **, P < 0.01; ***, P < 
0.001. 
 
  
Table 1. Genome-wide significant signals associated with LADA. 
 
SNP Chr Position 
(b37) 
Ref/other 
alle le  
Effect allele frq 
(cases/ctrls) 
O R 95% CI P Gene 
LADA (n =2,713) vs. population controls (n =5,439) 
rs9273368 6 32626475 A/G 0.499/0.279 3.116 2.859-3.396 2.23x10
-146
 HLA-DQB1 
rs2476601 1 114377568 A/G 0.158/0.102 1.711 1.534 -1.908 5.71x10
-22
 PTPN22 
rs689 11 2182224 T/A 0.272/0.197 1.480 1.361-1.610 1.01x10
-19
 INS 
rs7310615 12 111865049 C/G 0.487/0.459 1.302 1.209 -1.401 2.93x10
-12
 SH2B3 
LADA (n = 2,533) vs. T1D cases (n = 971) 
rs9273368 6 32626475 A/G 0.415/0.649 0.340 0.289-0.399 8.69x10
-40
 HLA-DQB1 
LADA (n = 2,858) vs. T2D cases (n = 10,444) 
rs9273364 6 32626302 G/T  0.426/0.296 2.447 2.231-2.684 3.46x10
-80
 HLA-DQB1 
rs689 11 2182224 T/A 0.783/0.715 1.475 1.355-1.606 2.72x10
-19
 INS 
rs2476601 1 114377568 A/G 0.142/0.103 1.590 1.420-1.779 7.41x10
-16
 PTPN22 
rs6908626 6 91005743 T/G 0.201/0.164 1.35 1.218-1.491 7.3x10
-9
 BACH2 
rs3184504 12 111884608 C/T  0.544/0.520 1.242 1.155-1.339 8.33x10
-9
 SH2B3 
We performed three genome-wide association approaches, first for LADA versus population 
controls (top panel), then for LADA versus type 1 diabetes (T1D, middle panel) and LADA 
versus type 2 diabetes (T2D, lower panel). Odds ratios (ORs) are given for the LADA risk allele 
except for rs92773368 in LADA vs. T1D, to illustrate that the T1D risk allele was depleted in 
LADA. 
